T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

T-ACE Oil

TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.

DRUG

Lipiodol

TAE/TACE treatment was performed with Lipiodol. The volume of Lipiodol injected would be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor. The maximum dose is 0.25 mL/kg/day but not over 15 mL for each treatment.

Trial Locations (4)

100

RECRUITING

National Taiwan University Hospital, Taipei

435

RECRUITING

Tungs' Taichung Metroharbor Hospital, Taichung

701

RECRUITING

National Cheng Kung University Hospital, Tainan City

813

RECRUITING

Kaohsiung Veterans General Hospital, Kaohsiung City

All Listed Sponsors
lead

T-ACE Medical Co., Ltd

INDUSTRY